Veradigm Health joins Harvard Pilgrim to develop next phase of FDA’s Sentinel System
Five-year award signals FDA’s commitment to national program utilizing electronic healthcare data to monitor the safety of
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005125/en/
According to the
As a business unit of Allscripts, one of the world’s largest EHR providers, Veradigm is especially well positioned to help the Harvard Pilgrim team achieve FDA’s objective to better utilize information from EHRs in the next phase of Sentinel development. Veradigm currently offers HealthInsights, the largest deidentified EHR database available for life sciences research (~150m patients) that has been linked to integrated claims for certain research studies. In addition, Veradigm collaborates with healthcare providers to implement point-of-care research programs, engaging patients and prospectively collecting additional data using Allscripts EHR platforms.
“Veradigm is excited to collaborate with Harvard Pilgrim to continue to advance the Sentinel System,” said
About Veradigm™
Veradigm is an integrated data systems and services business that combines data-driven clinical insights with actionable tools for clinical workflow, research, analytics, and media. Our solutions are designed to help key healthcare stakeholders to improve the quality, efficiency, and value of healthcare delivery - from biopharma to health plans, healthcare providers, health technology partners, and most importantly, the patients they serve. We are dedicated to simplifying the complicated healthcare system with next-generation healthcare solutions. That is how we are transforming health, insightfully. To learn more, visit www.veradigmhealth.com. Veradigm™ is a business unit of Allscripts.
About Allscripts
© 2019
Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005125/en/
Source: Allscripts
Investors:
Stephen Shulstein
312-386-6735
Stephen.Shulstein@allscripts.com
Media:
Tom Lynch
312-386-6765
Tom.Lynch@allscripts.com